These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 29287992)

  • 1. Comorbidity, concomitant medication, use of resources and healthcare costs associated with chronic hepatitis C virus carriers in Spain.
    Sicras-Mainar A; Navarro-Artieda R; Sáez-Zafra M
    Gastroenterol Hepatol; 2018 Apr; 41(4):234-244. PubMed ID: 29287992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of the potential drug-drug interactions between pangenotypic direct-acting antivirals and the concomitant medications associated with patients with chronic hepatitis C virus infection in Spain.
    Sicras Mainar A; Navarro Artieda R; Hernández I; Morillo R
    Gastroenterol Hepatol; 2019 Oct; 42(8):465-475. PubMed ID: 31451229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective.
    McAdam-Marx C; McGarry LJ; Hane CA; Biskupiak J; Deniz B; Brixner DI
    J Manag Care Pharm; 2011 Sep; 17(7):531-46. PubMed ID: 21870894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus.
    Sicras-Mainar A; Navarro-Artieda R; Morano R; Ruíz L
    Endocrinol Nutr; 2016 Dec; 63(10):527-535. PubMed ID: 27744013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic Impact of Atopic Dermatitis in Adults: A Population-Based Study (IDEA Study).
    Sicras-Mainar A; Navarro-Artieda R; Carrascosa Carrillo JM
    Actas Dermosifiliogr (Engl Ed); 2018; 109(1):35-46. PubMed ID: 29126499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics, healthcare costs, and resource utilization in hepatitis C vary by genotype.
    Goolsby Hunter A; Rosenblatt L; Patel C; Blauer-Peterson C; Anduze-Faris B
    Curr Med Res Opin; 2017 May; 33(5):829-836. PubMed ID: 28128648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection.
    Gordon SC; Pockros PJ; Terrault NA; Hoop RS; Buikema A; Nerenz D; Hamzeh FM
    Hepatology; 2012 Nov; 56(5):1651-60. PubMed ID: 22610658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy.
    Backx M; Lewszuk A; White JR; Cole J; Sreedharan A; van Sanden S; Diels J; Lawson A; Neal KR; Wiselka MJ; Ito T; Irving WL
    J Viral Hepat; 2014 Mar; 21(3):208-15. PubMed ID: 24438682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of high healthcare resource utilization and liver disease progression among patients with chronic hepatitis C.
    LaMori J; Tandon N; Laliberté F; Germain G; Pilon D; Lefebvre P; Prabhakar A
    J Med Econ; 2016; 19(4):364-73. PubMed ID: 26624985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HEPATITIS C IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM: BURDEN OF DISEASE.
    Castelo A; Mello CEB; Teixeira R; Madruga JVR; Reuter T; Pereira LMMB; Silva GF; Álvares-DA-Silva MR; Zambrini H; Ferreira PRA
    Arq Gastroenterol; 2018; 55(4):329-337. PubMed ID: 30785514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost.
    Tandon N; Balart LA; Laliberté F; Pilon D; Lefebvre P; Germain G; Prabhakar A
    J Med Econ; 2014 Dec; 17(12):862-71. PubMed ID: 25215925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic burden of cirrhosis in Catalonia: a population-based analysis.
    Miquel M; Clèries M; Vergara M; Vela E
    BMJ Open; 2018 Mar; 8(3):e018012. PubMed ID: 29502082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic impact of heart failure according to the effects of kidney failure.
    Sicras Mainar A; Navarro Artieda R; Ibáñez Nolla J
    Rev Esp Cardiol (Engl Ed); 2015 Jan; 68(1):39-46. PubMed ID: 25553938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact on healthcare resource utilization of multiple sclerosis in Spain.
    Sicras-Mainar A; Ruíz-Beato E; Navarro-Artieda R; Maurino J
    BMC Health Serv Res; 2017 Dec; 17(1):854. PubMed ID: 29284493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of hepatitis C treatment response on medical costs: a longitudinal analysis in an integrated care setting.
    Manos MM; Darbinian J; Rubin J; Ray GT; Shvachko V; Denis B; Velez F; Quesenberry C
    J Manag Care Pharm; 2013; 19(6):438-47. PubMed ID: 23806057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment patterns, comorbidities, healthcare resource use, and associated costs by line of chemotherapy and level of comorbidity in patients with newly-diagnosed Merkel cell carcinoma in the United States.
    Kearney M; Thokagevistk K; Boutmy E; Bharmal M
    J Med Econ; 2018 Dec; 21(12):1159-1171. PubMed ID: 30149739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia.
    Poordad F; Theodore D; Sullivan J; Grotzinger K
    J Med Econ; 2011; 14(2):194-206. PubMed ID: 21348807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
    Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
    J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Use of resources and associated costs of chronic obstructive pulmonary disease exacerbations: A population based retrospective study].
    Sicras A; Huerta A; Navarro R; Ibañez J
    Semergen; 2014; 40(4):189-97. PubMed ID: 24485969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic impact of health resource optimisation in the approach to patients with hepatitis C.
    Turnes J; García F; Diago M; Andrade RJ; Díaz P; Rubio-Rodríguez D; Rubio-Terrés C
    Gastroenterol Hepatol; 2019 Sep; 42 Suppl 1():26-33. PubMed ID: 32560770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.